6.42
0.28 (4.56%)
| Previous Close | 6.14 |
| Open | 6.07 |
| Volume | 85,576 |
| Avg. Volume (3M) | 94,132 |
| Market Cap | 54,030,720 |
| Price / Sales | 0.250 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Profit Margin | -52.62% |
| Operating Margin (TTM) | -102.42% |
| Diluted EPS (TTM) | -13.95 |
| Quarterly Revenue Growth (YOY) | -9.50% |
| Current Ratio (MRQ) | 1.70 |
| Operating Cash Flow (TTM) | -127.49 M |
| Levered Free Cash Flow (TTM) | -77.12 M |
| Return on Assets (TTM) | -36.88% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Karyopharm Therapeutics Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | -3.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.30 |
|
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.86% |
| % Held by Institutions | 48.43% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 56.00 (HC Wainwright & Co., 772.27%) | Buy |
| Median | 54.00 (741.12%) | |
| Low | 3.00 (RBC Capital, -53.27%) | Buy |
| Average | 37.67 (486.76%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 8.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 03 Mar 2025 | 54.00 (741.12%) | Buy | 7.25 |
| HC Wainwright & Co. | 26 Feb 2025 | 56.00 (772.27%) | Buy | 9.83 |
| 20 Feb 2025 | 7.00 (9.03%) | Buy | 9.15 | |
| RBC Capital | 20 Feb 2025 | 3.00 (-53.27%) | Buy | 9.15 |
| 10 Feb 2025 | 3.00 (-53.27%) | Buy | 9.35 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 May 2025 | Announcement | Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 01 Apr 2025 | Announcement | Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 03 Mar 2025 | Announcement | Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 24 Feb 2025 | Announcement | Karyopharm Announces 1-for-15 Reverse Stock Split |
| 19 Feb 2025 | Announcement | Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress |
| 12 Feb 2025 | Announcement | Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |